Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 6, 1998, Pages 1906-1910

  Singer, Frederick R ^a   Clemens, Thomas L ^b   Eusebio, Rachelle A ^c   Bekker, Pirow J ^c  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITONIN; CALCITRIOL; CALCIUM; CREATININE; HYDROXYPROLINE; MITHRAMYCIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHORUS; RISEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE URINE LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKERS; CREATININE; ETIDRONIC ACID; FEMALE; HUMANS; HYDROXYPROLINE; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; PARATHYROID HORMONE; PHOSPHORUS;

EID: 0031762884     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.6.1906     Document Type: Article

References (38)

1. Smith R, Russell RGG, Bishop M. 1971 Diphosphonates and Paget's disease of bone. Lancet. 1:945-947.
2. Schmorl G. 1932 Über Ostitis deformans Paget. Virchows Arch Pathol Anat Physiol. 283:694-751.
3. Singer FR, Minoofar P. 1995 Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab. 6:259-288.
4. Meunier PJ, Ravault A. 1991 Treatment of Paget's disease with etidronate disodium. In: Singer FR, Wallach S, eds. Paget's disease of bone. Clinical assessment, present and future therapy. New York: Elsevier; 86-99.
5. Roux C, Gennari C, Farrerons J, et al. 1995 Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 38:851-858.
6. Singer FR, Fredericks RS, Minkin C. 1980 Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum. 23:1148-1154.
7. Ryan WG, Schwartz TB, Perlia CP. 1969 Effects of mithramycin on Paget's disease of bone. Ann Intern Med. 70:549-557.
8. Mitchell DY, Eusebio RA, Heise MA, et al. 1996 The effect of dosing regimen on the pharmacokinetics of risedronate administered to healthy subjects. J Bone Miner Res. 11(Suppl 1):M661.
9. Meier DE, Luckey MM, Wallenstein S, Clemens TL, Orwoll ES, Waslein CI. 1991 Calcium, vitamin D, and parathyroid hormone status in young white and black women: association with racial differences in bone mass. J Clin Endocrinol Metab. 72:7113-710.
10. Blumenkrantz N, Asboe-Hanson G. 1973 A quick and specific assay for hydroxyproline. Anal Biochom. 55:288-291.
11. Siris E, Weinstein RS, Altman R, et al. 1996 Comparative study of alendronate vs. etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 81:961-967.
12. Reid IR, Nicholson GC, Weinstein RS, et al. 1996 Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med. 101:341-348.
13. Reginster JY, Jeugmans-Huynen AM, Albert A, et al. 1988 Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone. 9:349-354.
14. Khairi MRA, Altman RD, DeRosa GP, Zimmerman J, Schenk RK, Johnston CC. 1477 Sodium etidronate in the treatment of Paget's disease of bone. Ann Intern Med. 87:656-663.
15. Siris ES, Canfield RE, Jacobs TP, Baquiran DC. 1980 Long-term therapy of Paget's disease of bone with EHDP. Arthritis Rheum. 23:1177-1184.
16. Johnston Jr CC, Khairi MRA, Meunier PJ. 1980 Use of etidronate (EHDP) in Paget's disease of bone. Arthritis Rheum. 23:1172-1176.
17. Delmas PD, Chapuy MC, Vignon E, et al. 1982 Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab. 54:837-844.
18. 2 MDP) on Paget's disease of bone. Adv Exp Med Biol. 128:299-304.
19. Frijlink WB, Bijvoet OLM, Te Velde J, Heynen G. 1479 Treatment of Paget's disease with (3-amino-1-hydroxvpropylidene)-1,1-bisphosphonate (APD). Lancet. 1:799-803.
20. Fraser TRC, Ibbertson HF, Holdaway IM, et al. 1984 Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1, 1-bisphosphonate): a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1, 1-bisphosphonate). Aust NZ J Med. 14:811-818.
21. Deleted in proof.
22. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. 1994 Bisphosphonates: structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA, eds. Bone and mineral research. Amsterdam: Elsevier; 265-306.
23. Brown JP, Johnston Jr CC, Reginster J-Y, Ryan WG, Ste-Marie L-G, Bekker PJ. Dose response of risedronate for Paget's disease. Proc of the 79th Meeting of The Endocrine Society. 1997; 488.
24. Boyle I, Brown J, Davies J, et al. 1992 Risedronate: preliminary results on dose dependency of cumulative doses of a bisphosphonate in pagotic patients. J Bone Miner Res. 7:S299.
25. Mitchell DY, Eusebio RA, Heise MA, et al. 1996 The effect of dosing regimen on the pharmacokinetics of risedronate administered to healthy subjects. J Bone Miner Res. 11(Suppl 1):M661.
26. Gertz BJ, Holland SD, Kline WF, et al. 1995 Studies of the oral bioavailabilitv of alendronate. Clin Pharmacol Ther. 53:288-298.
27. De Groen PC, Lubbe DF, Hirsch LJ, et al. 1996 Esophagitis associated with the use of alendronate. N Engl J Med. 335:1016-1020.
28. Castell DO. 1996 "Pill esophagitis" - the case of alendronate. N Engl J Med. 335:1058-1059.
29. Sorrentino D, Trevisi A, Bernardis V, DeBiase F, Labombarda A, Bartoli E. 1996 Esophageal ulceration due to alendronate. Endoscopy. 28:529.
30. Naylor G, Davies MH. 1996 Oesophageal stricture with alendronic acid. Lancet. 348:1030-1031.
31. Maconi G, Bianchi Porro G. 1995 Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol. 90:1889-1890.
32. Abdelmalek MF, Douglas DD. 1996 Alendronate-induced ulcerative esophagitis. Am J Gastroenterol. 91:1282-1283.
33. Lufkin EG, Argueta R, Whitaker MD, et al. 1994 Pamidronate; an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 4:320-322.
34. Smith R, Russell RGG. 1972 Treatment of Paget's disease with a diphosphonate (sodium etidronate). Semin Drug Treat. 2:77-81.
35. Stein IS, Shapiro B, Ostrum B, Beller ML. 1977 Evaluation of sodium etidronate in the treatment of Paget's disease of bone. Clin Orthop. 122:347-358.
36. +-ATPase. J Bone Miner Res. 11:1498-1507.
37. Bekker PJ, Gay CV. 1990 Biochemical characterization of an electrogenic vacuolar proton pump in purified chicken osteoclast plasma membrane vesicles. J Bone Miner Res. 5:569-579.
38. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. 1989 Osteoclastic bone resorption by a polarized vacuolar proton pump. Science. 245:855-857.